SGH
SRPT icon

Sivik Global Healthcare’s Sarepta Therapeutics SRPT Stock Holding History

Sivik Global Healthcare’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$1.28M – 48
2025
Q1 		$1.28M Buy
+20,000
New +$2.11M 0.69% 30

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Sivik Global Healthcare's SRPT Position: Q1 2025 in Review

Sivik Global Healthcare sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 10,000 shares — an estimated $1.05M sold.

Sivik Global Healthcare first reported a position in SRPT in Q4 2017 and held it in 15 quarters. The position peaked at $4.18M in Q2 2019. 431 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Sivik Global Healthcare reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sivik Global Healthcare sold 10,000 Sarepta Therapeutics shares in Q1 2025, an estimated $1.05M.
  • Sivik Global Healthcare first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 15 quarters.
  • Sivik Global Healthcare's Sarepta Therapeutics position peaked at $4.18M in Q2 2019.
  • 431 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Sivik Global Healthcare's 13F filing for Q1 2025, filed 22 Apr 2025.